PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $21.00 target price on the stock.

Several other research analysts also recently commented on PDSB. B. Riley cut their target price on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Price Performance

PDSB stock opened at $1.54 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 52-week low of $1.20 and a 52-week high of $6.68. The company has a market capitalization of $57.61 million, a P/E ratio of -1.33 and a beta of 1.88. The company has a fifty day moving average price of $1.54 and a 200-day moving average price of $2.44.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP lifted its stake in shares of PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after purchasing an additional 48,132 shares during the period. Jane Street Group LLC bought a new stake in PDS Biotechnology in the fourth quarter worth approximately $58,000. Marshall Wace LLP lifted its stake in PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after buying an additional 10,837 shares during the period. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $26,000. Finally, Renaissance Technologies LLC grew its position in shares of PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after buying an additional 76,800 shares during the period. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.